On August 30, 2025, Novartis revealed encouraging findings from the V-DIFFERENCE study - a Phase IV trial comparing Leqvio® (inclisiran) to a placebo alongside optimized lipid-lowering therapy (LLT) in individuals with high cholesterol that haven't met the recommended LDL-C targets. The results will be showcased at a Hot Line session during the 2025 European Society of Cardiology Congress in Madrid, Spain, taking place from August 29 to September 1, 2025.